IL134191A0 - Composition and method for treating penile erectile dysfunciton - Google Patents

Composition and method for treating penile erectile dysfunciton

Info

Publication number
IL134191A0
IL134191A0 IL13419198A IL13419198A IL134191A0 IL 134191 A0 IL134191 A0 IL 134191A0 IL 13419198 A IL13419198 A IL 13419198A IL 13419198 A IL13419198 A IL 13419198A IL 134191 A0 IL134191 A0 IL 134191A0
Authority
IL
Israel
Prior art keywords
composition
prostaglandin
dysfunciton
penile erectile
skin
Prior art date
Application number
IL13419198A
Original Assignee
Macrochem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corp filed Critical Macrochem Corp
Publication of IL134191A0 publication Critical patent/IL134191A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition for the topical transdermal administration to the penis is based on prostaglandin E1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E1 active ingredient through the skin. Phentolamine or prazosin may be used in combination with prostaglandin E1.
IL13419198A 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunciton IL134191A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/012284 WO1999065303A1 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Publications (1)

Publication Number Publication Date
IL134191A0 true IL134191A0 (en) 2001-04-30

Family

ID=22267309

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13419198A IL134191A0 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunciton

Country Status (18)

Country Link
US (1) US5942545A (en)
EP (1) EP1026947B1 (en)
JP (1) JP3513764B2 (en)
KR (1) KR20010022296A (en)
CN (1) CN1206998C (en)
AT (1) ATE209856T1 (en)
AU (1) AU764437B2 (en)
BR (1) BR9811797A (en)
CA (1) CA2296373C (en)
DE (1) DE69802838T2 (en)
DK (1) DK1026947T3 (en)
ES (1) ES2170503T3 (en)
HK (1) HK1030133A1 (en)
HU (1) HU224318B1 (en)
IL (1) IL134191A0 (en)
NO (1) NO20000157L (en)
PL (1) PL189436B1 (en)
WO (1) WO1999065303A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
GR1002847B (en) 1997-05-06 1998-01-27 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
GR1003199B (en) 1998-08-14 1999-09-01 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction
FR2789586A1 (en) * 1999-02-16 2000-08-18 Synthelabo Compositions containing alfuzosin for treatment of erectile dysfunction, applied by balanic transmucosal administration
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
MXPA01008955A (en) 1999-03-05 2002-04-24 Procter & Gamble C16.
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6582683B2 (en) 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100402334B1 (en) * 2000-06-23 2003-10-22 환인제약 주식회사 Alprostadil-containing composition for external application
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6949526B2 (en) * 2000-07-31 2005-09-27 Ono Pharmaceutical Co., Ltd. Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR100649860B1 (en) * 2000-09-01 2006-11-24 주식회사종근당 Transmucosal and transdermal delivery preparation of alprostadil
KR20020020536A (en) * 2000-09-09 2002-03-15 장우영 Injection for impotency
KR100373540B1 (en) * 2000-09-20 2003-02-25 최한곤 Composite of transurethral suppository containing prostaglandin E1
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
CN100581544C (en) * 2001-03-05 2010-01-20 美国医疗产品公司 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
HU225597B1 (en) * 2001-03-30 2007-05-02 Futura Medical Dev Ltd Condom with an erectogenic compound or composition and use of an erectogenic compound or composition for the manufacture of a medicament and use of an erectogenic compound for preparation of a composition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6756059B2 (en) 2001-08-20 2004-06-29 Skinvisible Pharmaceuticals, Inc. Topical composition, topical composition precursor, and methods for manufacturing and using
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
KR100446960B1 (en) * 2001-12-04 2004-09-01 김종국 Composition of thermosensitive emulsion for external use of prostaglandin E1
KR100810404B1 (en) * 2001-12-18 2008-03-04 환인제약 주식회사 Alprostadil alkyl ester-containing composition for external application
US6673841B2 (en) 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
US20030220292A1 (en) * 2002-02-15 2003-11-27 Nexmed (Holdings), Inc. Treatment of erectile dysfunction
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040126339A1 (en) * 2002-12-31 2004-07-01 Roszell James A. Sunscreen composition and methods for manufacturing and using a sunscreen composition
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR101086147B1 (en) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 Compositions and methods for treatment of premature ejaculation
JP2006520788A (en) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド Angiogenesis promotion and method by prostaglandin composition
JP2006522136A (en) * 2003-04-02 2006-09-28 ネックスメド ホールディングス インコーポレイテッド Prostaglandin composition and its use for the treatment of vasospasm
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
BRPI0418589A (en) 2003-12-08 2008-01-29 Bentley Pharmaceuticals Inc pharmaceutical compositions and methods for insulin treatment
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
TR201815853T4 (en) 2005-10-12 2018-11-21 Besins Healthcare Sarl Testosterone gel for use in the treatment of hypogonadism.
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20100137333A1 (en) * 2006-10-20 2010-06-03 Roszell James A Antifungal composition and methods for using
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8128913B1 (en) 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
BRPI0800596A2 (en) 2008-01-31 2009-09-22 Univ Minas Gerais method for potentiation of erectile function through the use of pharmaceutical compositions of the toxin tx2-6 from the phoneutria nigriventer spider
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
CA2838109C (en) 2011-04-07 2020-06-09 Nexmed Holdings, Inc. Topical semisolid prostaglandin e1 composition for treating raynaud's disease
MX2022007009A (en) * 2019-12-09 2022-08-25 Futura Medical Developments Ltd Topical composition and methods of measuring the cooling abaility of a topical composition.
CA3074150A1 (en) 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
EP4232002A1 (en) * 2020-10-22 2023-08-30 Standard International Group Holdings, LP Transdermal treatment for erectile dysfunction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (en) * 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (en) * 1989-07-11 1991-09-27 Virag Ronald VASO-ACTIVE MEDICINE
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
IT1252603B (en) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
IT1247678B (en) * 1990-05-31 1994-12-28 Alberto Reale METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
DE4117249C2 (en) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomine used to treat erectile dysfunction
WO1993012788A1 (en) * 1991-12-23 1993-07-08 The Upjohn Company Pyridylguanidine compounds for treatment of erectile dysfunction
DE69320378T2 (en) * 1992-01-21 1999-04-29 Macrochem Corp Iontophoretic improved drug delivery
US5400094A (en) * 1993-03-31 1995-03-21 Minnesota Mining And Manufacturing Company Condensers for overhead projectors
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5587167A (en) * 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5451609A (en) * 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin

Also Published As

Publication number Publication date
JP3513764B2 (en) 2004-03-31
NO20000157L (en) 2000-02-09
JP2000511944A (en) 2000-09-12
US5942545A (en) 1999-08-24
DE69802838D1 (en) 2002-01-17
PL189436B1 (en) 2005-08-31
DE69802838T2 (en) 2002-06-27
NO20000157D0 (en) 2000-01-12
PL338787A1 (en) 2000-11-20
DK1026947T3 (en) 2002-04-02
EP1026947A1 (en) 2000-08-16
AU7838798A (en) 2000-01-05
AU764437B2 (en) 2003-08-21
HUP0103346A2 (en) 2002-01-28
HUP0103346A3 (en) 2004-06-28
BR9811797A (en) 2000-09-26
CN1206998C (en) 2005-06-22
EP1026947A4 (en) 2000-10-25
CA2296373A1 (en) 1999-12-23
EP1026947B1 (en) 2001-12-05
HK1030133A1 (en) 2001-04-27
CA2296373C (en) 2003-08-12
CN1267191A (en) 2000-09-20
ES2170503T3 (en) 2002-08-01
ATE209856T1 (en) 2001-12-15
HU224318B1 (en) 2005-07-28
KR20010022296A (en) 2001-03-15
WO1999065303A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
HK1030133A1 (en) Composition and method for treating penile erectile dysfunction
MXPA03001858A (en) Method for treating erectile dysfunction and increasing libido in men.
DE69933128D1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EFFECTIVE DYSFUNCTION
NZ520015A (en) Hydroxide-releasing agents as skin permeation enhancers
AU620282B2 (en) Method of treating impotence
EA200001043A3 (en) I:npy inhibitor for treating female sexual dysfunction
GR3032251T3 (en) Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
CA2352552A1 (en) Treatment of erectile dysfunction
BR9911408A (en) Dosage forms containing apomorphine for improvement of male erectile dysfunction
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
EP1007013A4 (en) Parenteral pimaricin as treatment of systemic infections
AU8419101A (en) Transdermal pharmaceutical delivery composition
ATE303804T1 (en) TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS
CA2377373A1 (en) Nitric oxide donors for inducing neurogenesis
IL131811A0 (en) Antitussive compositions
WO1999030718A3 (en) PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
WO2000002550A3 (en) Acetylpiperazines for modulating sexual activity
KR900005974A (en) Sexual Dysfunction in Men
GR3023448T3 (en) Pyridylguanidine compounds for treatment of erectile dysfunction.
WO2004084861A3 (en) Angiogenesis promotion by prostaglandin compositions and methods
RU2000101317A (en) COMPOSITION AND METHOD OF TREATMENT OF DISORDERS OF PERFORMANCE OF THE PURPOSE
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction
MXPA02010115A (en) Enhanced compositions for the treatment of male erectile dysfunction.

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees